Tiapride


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Behavioural disorders; Dyskinesia 200-400 mg/day. Dyskinesia: Higher daily doses may be needed.
Dosage Details
Oral
Behavioural disorders, Dyskinesia
Adult: 200-400 mg daily. Higher daily doses may be required in dyskinesias.
Contraindications
Coma, CNS depression, phaeochromocytoma, prolactin dependent tumours, bone marrow suppression.
Special Precautions
CV disease, Parkinson's disease, epilepsy, depression, myasthenia gravis, paralytic ileus, prostatic hypertrophy, blood dyscrasias. Elderly.
Adverse Reactions
Parkinsonian symptoms, drowsiness, agitation, insomnia, convulsions, dizziness, nasal congestion, antimuscurinic symptoms (e.g. dry mouth, constipation, blurred vision, difficulty with micturition and mydriasis), ECG changes, cardiac arrhythmias, orthostatic hypotension, photosensitisation, corneal and lens opacities. Delirium, nightmare, depression, inhibition of ejaculation, impotence, priapism, hypersensitivity reactions.
Potentially Fatal: Blood dyscrasias, neuroleptic malignant syndrome.
Drug Interactions
Increased risk of neuroleptic malignant syndrome with benzodiazepines. Increased risk of CNS depression with other CNS depressants e.g. general anaesthetics, hypnotics, anxiolytics and opioids. Increased antimuscarinic side effects with TCAs and antiparkinsonian drugs. Antagonised effects of dopaminergic drugs e.g. bromocriptine. Increased risk of QT interval prolongation with drugs that may prolong QT interval.
Action
Description: Tiapride is an atypical neuroleptic agent with selective dopamine D2-receptor antagonist activity and has general properties similar to sulpiride. It is unlikely to cause catalepsy and sedation and is used in the management of behaviour disorders and to treat dyskinesias.
Pharmacokinetics:
Absorption: Rapidly absorbed from GI tract. Peak plasma concentrations:1-2 hr.
Distribution: Distributed into breast milk
Excretion: Excreted largely unchanged in the urine. Plasma half-life : 3-4 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Tiapride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in